MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202521015428 A) filed by Rungta International Skills University; Rungta College Of Engineering & Technology; and Rungta College Of Pharmaceutical Sciences And Research on February 22, 2025, for A Device For Ai-Assisted Nanotechnology-Based Targeted Drug Delivery For Breast Cancer.
Inventors include Prof Prabhjeet Kaur; Shahnawaz Hussain; Lokendra Gavel; Shreeparna Dutta; Debangana Das; Sharmistha Chatterjee; Abhigyan Pandey; Kamlesh Kumar; Md Raza Ali; and Sonam Bharti.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: A Device for AI-Assisted Nanotechnology-Based Targeted Drug Delivery for Breast Cancer This invention describes an AI-assisted nanotechnology device for targeted drug delivery, designed to optimize the treatment of breast cancer and other conditions requiring precision therapeutics. The device integrates advanced nanoparticle synthesis, sterile drug encapsulation, and programmable release mechanisms to ensure site-specific delivery while minimizing systemic toxicity. Utilizing microfluidic reactors, it produces biocompatible nanoparticles with precise size, shape, and functionalization, tailored for active or passive targeting. An AI-assisted targeting module analyzes patient-specific tumor biomarkers and dynamically adjusts nanoparticle features and release profiles for personalized therapy. Real-time monitoring through embedded sensors provides feedback to refine treatment strategies, ensuring adaptive and effective therapeutic outcomes. The device is user-friendly, portable, and compliant with regulatory standards, offering scalability and compatibility with various therapeutic agents. By addressing the limitations of traditional treatments, this invention delivers a safer, more efficient, and personalized approach to advanced medical care.
Disclaimer: Curated by HT Syndication.
